Track the 엔지켐생명과학 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are listed on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 엔지켐생명과학 has recorded 113 reports. Market capitalisation: €83.8bn. The latest transaction was reported on 1 June 2026 (Purchase). Among the most active insiders: 윤영배. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 113 declarations
엔지켐생명과학 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for disease treatment.